Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.4263 | 0.4263 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.4263 | 0.4001 |
Onchocerca volvulus | 0.0033 | 0.4263 | 0.5 | |
Echinococcus multilocularis | musashi | 0.0033 | 0.4263 | 0.4263 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.4263 | 0.4263 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0438 | 0.0438 |
Echinococcus multilocularis | lamin | 0.0033 | 0.4263 | 0.4263 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.4113 | 0.4113 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.4263 | 0.4263 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.4263 | 0.4263 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Onchocerca volvulus | 0.0033 | 0.4263 | 0.5 | |
Echinococcus granulosus | lamin | 0.0033 | 0.4263 | 0.4263 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.4263 | 0.4263 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.4263 | 0.4263 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.4263 | 0.4001 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 1.122 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.